Gan You
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gan You has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Tao Jiang
Beijing Neurosurgical Institute, Capital Medical University, Beijing, China
4 shared publications Wei Zhang
Beijing Neurosurgical Institute, Capital Medical University, Beijing 100050, China; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China; Chinese Glioma Cooperative Group (CGCG), China
3 shared publications- Yinyan Wang
Beijing Neurosurgical Institute, Capital Medical University, Beijing, China; Beijing Institute for Brain Disorders, Beijing, China; National Clinical Research Center of Neurological Diseases, Beijing, China; Chinese Glioma Genome Atlas Network, China
3 shared publications Pei Yang
Beijing Neurosurgical Institute, Capital Medical University, Beijing 100050, China; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China; Chinese Glioma Cooperative Group (CGCG), China
2 shared publicationsTao Jiang
2 shared publicationsTingyu Liang
Beijing Ditan Hospital, Beijing, China
2 shared publications
Latest Publications
- 5 November 2018
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 20 (suppl_6) , vi167
PATH-38. CORRELATION OF ALTERATION OF HLA-F EXPRESSION AND CLINICAL CHARACTERIZATION IN 593 BRAIN GLIOMA SAMPLES
Human gliomas are highly fatal tumor with a significant feature of immune suppression. The immune system in glioma is gradually revealed, and immunotherapy is expected to improve the survival of glioma patients. With a deep understanding of the immune microenvironment of glioma, immunotherapy of gliomas has been increased exponentially in recent years. Searching for key regulators of immune response in glioma will provide clinical targets for immunotherapy. In our research, we focus on human leukocyte antigen (HLA) system, responsible for regulating the immune system, and discovered the relationship between HLA-F expression and clinical prognosis in gliomas. A total of 593 gliomas patients are concluded in our research, 325 patients from Chinese Glioma Genome Atlas (CGGA) and 268 patients from GSE 16011 set. Kaplan-Meier (KM) analysis is performed to explore the prognostic value of HLA-F. T test analysis is used to find the distribution difference in various groups. R language packages are used for other statistical computations and figures drawing. HLA-F was significantly negatively correlated with overall survival (OS) in all grade gliomas and glioblastoma (GBM). Moreover, HLA-F was enriched in GBM and IDH1 wild-type group, and HLA-F was a mesenchymal subtype marker. Pearson correlation test showed that HLA-F was correlated with other HLA-I molecules. HLA-F expression was positively with malignant phenotype and negatively with OS indicating that HLA-F could predict the immune state in glioma, and might be a clinical target of glioma immunotherapy. Key Words: HLA-F; glioma; immunotherapy; OS
- 5 November 2018
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 20 (suppl_6) , vi167
PATH-38. CORRELATION OF ALTERATION OF HLA-F EXPRESSION AND CLINICAL CHARACTERIZATION IN 593 BRAIN GLIOMA SAMPLES
Human gliomas are highly fatal tumor with a significant feature of immune suppression. The immune system in glioma is gradually revealed, and immunotherapy is expected to improve the survival of glioma patients. With a deep understanding of the immune microenvironment of glioma, immunotherapy of gliomas has been increased exponentially in recent years. Searching for key regulators of immune response in glioma will provide clinical targets for immunotherapy. In our research, we focus on human leukocyte antigen (HLA) system, responsible for regulating the immune system, and discovered the relationship between HLA-F expression and clinical prognosis in gliomas. A total of 593 gliomas patients are concluded in our research, 325 patients from Chinese Glioma Genome Atlas (CGGA) and 268 patients from GSE 16011 set. Kaplan-Meier (KM) analysis is performed to explore the prognostic value of HLA-F. T test analysis is used to find the distribution difference in various groups. R language packages are used for other statistical computations and figures drawing. HLA-F was significantly negatively correlated with overall survival (OS) in all grade gliomas and glioblastoma (GBM). Moreover, HLA-F was enriched in GBM and IDH1 wild-type group, and HLA-F was a mesenchymal subtype marker. Pearson correlation test showed that HLA-F was correlated with other HLA-I molecules. HLA-F expression was positively with malignant phenotype and negatively with OS indicating that HLA-F could predict the immune state in glioma, and might be a clinical target of glioma immunotherapy. Key Words: HLA-F; glioma; immunotherapy; OS
- 1 February 2016
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 35, 93-99
Clinicopathological factors predictive of postoperative seizures in patients with gliomas
- 1 February 2016
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 35, 93-99
Clinicopathological factors predictive of postoperative seizures in patients with gliomas
- 1 September 2015
- Published by Elsevier in Epilepsy Research
- Vol. 115, 145-146
Response to “Association of IDH1/2 mutation with preoperative seizure in low-grade gliomas: How strong is the evidence?”
- 1 September 2015
- Published by Elsevier in Epilepsy Research
- Vol. 115, 145-146
Response to “Association of IDH1/2 mutation with preoperative seizure in low-grade gliomas: How strong is the evidence?”
- 1 January 2015
- Published by Elsevier in Epilepsy Research
- Vol. 109, 100-105
IDH1/2 mutation is associated with seizure as an initial symptom in low-grade glioma: A report of 311 Chinese adult glioma patients
- 1 January 2015
- Published by Elsevier in Epilepsy Research
- Vol. 109, 100-105
IDH1/2 mutation is associated with seizure as an initial symptom in low-grade glioma: A report of 311 Chinese adult glioma patients
- Open Access
- 7 June 2014
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 12 (1) , 181
A single aspergillus fumigatus intracranial abscess in an immunocompetent patient with parietal lobe tumorectomy
Aspergillosis of the central nervous system is a rare fungal infection that is mainly reported in patients with immune deficiency, such as AIDS patients and organ transplant patients treated with immunosuppressive agents, and is uncommon among patients with intact immune function. We report here a rare case of intracranial aspergillosis in a patient who had previously undergone a parietal lobe tumorectomy. Aspergillus fumigatus was confirmed by histopathology, and susceptibility tests reported that this infection should respond to voriconazole. We believe the immunosuppression resulting from surgical trauma and glucocorticosteroid treatment may be contributing to the infection, and therefore management of these two factors may improve the prognosis.
- 7 June 2014
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 12 (1) , 181
Open AccessA single aspergillus fumigatus intracranial abscess in an immunocompetent patient with parietal lobe tumorectomy
Aspergillosis of the central nervous system is a rare fungal infection that is mainly reported in patients with immune deficiency, such as AIDS patients and organ transplant patients treated with immunosuppressive agents, and is uncommon among patients with intact immune function. We report here a rare case of intracranial aspergillosis in a patient who had previously undergone a parietal lobe tumorectomy. Aspergillus fumigatus was confirmed by histopathology, and susceptibility tests reported that this infection should respond to voriconazole. We believe the immunosuppression resulting from surgical trauma and glucocorticosteroid treatment may be contributing to the infection, and therefore management of these two factors may improve the prognosis.
- Open Access
- 29 August 2013
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 32 (1) , 59
Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type
Background: To date, no prognostic microRNAs (miRNAs) for isocitrate dehydrogenase 1 (IDH1) wild-type glioblastoma multiformes (GBM) have been reported. The aim of the present study was to identify a miRNA signature of prognostic value for IDH1 wild-type GBM patients using miRNA expression dataset from the The Cancer Genome Atlas (TCGA). Methods: Differential expression profiling analysis of miRNAs was performed on samples from 187 GBM patients, comprising 17 mutant-type IDH1 and 170 wild-type IDH1 samples. Results: A 23-micoRNA signature which was specific to the IDH1 mutation was revealed. Survival data was available for 140 of the GBM patients with wild-type IDH1. Using these data, the samples were characterized as high-risk or low-risk group according to the ranked protective scores for each of the 23 miRNAs in the 23-miRNA signature. Then, the 23 IDH1 mutation-specific miRNAs were classified as risky group and protective group miRNAs based on the significance analysis of microarrays d-score (SAM d-value) (positive value or negative value). The risky group miRNAs were found to be expressed more in the high-risk samples while the protective group miRNAs were expressed more in the low-risk samples. Patients with high protective scores had longer survival times than those with low protective scores. Conclusion: These findings show that IDH1 mutation-specific miRNA signature is a marker for favorable prognosis in primary GBM patients with the IDH1 wild type.
- 29 August 2013
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 32 (1) , 59
Open AccessIsocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type
Background: To date, no prognostic microRNAs (miRNAs) for isocitrate dehydrogenase 1 (IDH1) wild-type glioblastoma multiformes (GBM) have been reported. The aim of the present study was to identify a miRNA signature of prognostic value for IDH1 wild-type GBM patients using miRNA expression dataset from the The Cancer Genome Atlas (TCGA). Methods: Differential expression profiling analysis of miRNAs was performed on samples from 187 GBM patients, comprising 17 mutant-type IDH1 and 170 wild-type IDH1 samples. Results: A 23-micoRNA signature which was specific to the IDH1 mutation was revealed. Survival data was available for 140 of the GBM patients with wild-type IDH1. Using these data, the samples were characterized as high-risk or low-risk group according to the ranked protective scores for each of the 23 miRNAs in the 23-miRNA signature. Then, the 23 IDH1 mutation-specific miRNAs were classified as risky group and protective group miRNAs based on the significance analysis of microarrays d-score (SAM d-value) (positive value or negative value). The risky group miRNAs were found to be expressed more in the high-risk samples while the protective group miRNAs were expressed more in the low-risk samples. Patients with high protective scores had longer survival times than those with low protective scores. Conclusion: These findings show that IDH1 mutation-specific miRNA signature is a marker for favorable prognosis in primary GBM patients with the IDH1 wild type.
- 1 January 2013
- Vol. 93 (1) , 5-7
[Whole-genome messenger RNA profiling reveals genes involved in malignant progression of glioma].
To employ whole-genome messenger RNA profiling to identify the genes involved in malignant progression in glioma. The whole genome expressed genes were profiled in 220 glioma patients from the Chinese Glioma Genome Atlas (97 LGGs and 123 HGGs). The differential expressed genes between LGG and HGG were identified by SAM analysis. Microarray data were validated by immunohistochemistry. Among all the detected genes, the genes up-regulated mostly in high-grade glioma were IGFBP-2, CKLF, PTTG1, OSTCL and PTTG2 while those down-regulated mostly SEC31, RRP7B, HOOK3, SNRPN and CSMD3. Validation of IGFBP-2 with immunohistochemical staining showed a good correlation with the microarray data. A panel of potential genes of malignant transformation may serve as future targets of gene therapy for glioma.
- 1 January 2013
- Vol. 93 (1) , 5-7
[Whole-genome messenger RNA profiling reveals genes involved in malignant progression of glioma].
To employ whole-genome messenger RNA profiling to identify the genes involved in malignant progression in glioma. The whole genome expressed genes were profiled in 220 glioma patients from the Chinese Glioma Genome Atlas (97 LGGs and 123 HGGs). The differential expressed genes between LGG and HGG were identified by SAM analysis. Microarray data were validated by immunohistochemistry. Among all the detected genes, the genes up-regulated mostly in high-grade glioma were IGFBP-2, CKLF, PTTG1, OSTCL and PTTG2 while those down-regulated mostly SEC31, RRP7B, HOOK3, SNRPN and CSMD3. Validation of IGFBP-2 with immunohistochemical staining showed a good correlation with the microarray data. A panel of potential genes of malignant transformation may serve as future targets of gene therapy for glioma.
- 1 September 2011
- Vol. 124 (17) , 2584-8
Gene expression profiling reveals Ki-67 associated proliferation signature in human glioblastoma.
Everlasting cellular proliferation is the fundamental feature during gliomagenesis and Ki-67 is one of the classical proliferation markers in human glioblastoma multiforme (GBM). However, the driver genes or core pathways for cellular proliferation in GBM have not been elucidated systematically. We evaluated by immunohistochemistry the prognostic value of Ki-67 expression in the clinical outcome of 156 Chinese patients with GBM and a total of 64 GBM samples were selected for further Agilent genome-wide microarray analysis. On the basis of the microarray data from Tiantan (n = 64) and The Cancer Genome Atlas (TCGA) (n = 202) database, differentially expressed genes between the GBM subgroups with high or low level of Ki-67 expression were identified using Significance Analysis of Microarrays (SAM). Gene Ontology (GO) and KEGG Pathway analyses were then undertaken for the Ki-67 associated genes to identify the most significant biological processes and signaling pathways. We confirmed that Ki-67 was an independent prognostic indicator in the largest Chinese patient cohort of 156 GBM samples via immunohistochemical staining. Survival analysis of Ki-67 over-expression revealed a highly significant association with a worse clinical outcome (P = 0.010 for progression-free survival; P = 0.007 for overall survival). Comparative and integrated analysis between Tiantan and TCGA database identified a 247-gene "proliferation signature" (205 up-regulated and 42 down-regulated genes) that distinguished Ki-67 expression phenotypes. GO and KEGG Pathway analyses further indicated that Ki-67 expression phenotype was associated with distinct changes in gene expression associated with the regulation of cellular growth and proliferation. Proliferation marker Ki-67 is an independent prognostic indicator in Chinese GBM patients. And Ki-67 associated proliferation signature identified through genome-wide microarray analysis may provide potential targets for anti-proliferation therapy in GBM.
- 1 September 2011
- Vol. 124 (17) , 2584-8
Gene expression profiling reveals Ki-67 associated proliferation signature in human glioblastoma.
Everlasting cellular proliferation is the fundamental feature during gliomagenesis and Ki-67 is one of the classical proliferation markers in human glioblastoma multiforme (GBM). However, the driver genes or core pathways for cellular proliferation in GBM have not been elucidated systematically. We evaluated by immunohistochemistry the prognostic value of Ki-67 expression in the clinical outcome of 156 Chinese patients with GBM and a total of 64 GBM samples were selected for further Agilent genome-wide microarray analysis. On the basis of the microarray data from Tiantan (n = 64) and The Cancer Genome Atlas (TCGA) (n = 202) database, differentially expressed genes between the GBM subgroups with high or low level of Ki-67 expression were identified using Significance Analysis of Microarrays (SAM). Gene Ontology (GO) and KEGG Pathway analyses were then undertaken for the Ki-67 associated genes to identify the most significant biological processes and signaling pathways. We confirmed that Ki-67 was an independent prognostic indicator in the largest Chinese patient cohort of 156 GBM samples via immunohistochemical staining. Survival analysis of Ki-67 over-expression revealed a highly significant association with a worse clinical outcome (P = 0.010 for progression-free survival; P = 0.007 for overall survival). Comparative and integrated analysis between Tiantan and TCGA database identified a 247-gene "proliferation signature" (205 up-regulated and 42 down-regulated genes) that distinguished Ki-67 expression phenotypes. GO and KEGG Pathway analyses further indicated that Ki-67 expression phenotype was associated with distinct changes in gene expression associated with the regulation of cellular growth and proliferation. Proliferation marker Ki-67 is an independent prognostic indicator in Chinese GBM patients. And Ki-67 associated proliferation signature identified through genome-wide microarray analysis may provide potential targets for anti-proliferation therapy in GBM.